The advent of tyrosine kinase inhibitors (TKI) has revolutionised the treatment of chronic myeloid leukaemia (CML). Nevertheless, no specific tools are currently available to support follow-up and guarantee the adequate management of safety, adherence, and effectiveness altogether of TKI-based regimens. This study aimed to introduce a monitoring instrument tailored to patients undergoing TKI therapy for CML.
Data Source
A structured instrument proposal was developed after conducting an integrative review. The instrument was then evaluated by clinicians and laboratory professionals with expertise in onco-haematology, who assessed clarity, objectivity, practicality, and clinical relevance using a five-point Likert scale.
Data Summary
The model comprised three protocols designed to evaluate adherence, safety, and effectiveness of TKI therapy. During evaluation of the instrument, all assessed parameters achieved mean scores ≥ 3.0. By aligning with international guidelines, the instrument consolidates essential monitoring parameters, thereby enhancing clinical decision-making and supporting patient-centred care in CML.
Conclusion
Instruments of this nature are rare and represent an important challenge for healthcare teams managing CML patients. Considering that adherence and safety are critical determinants of therapeutic success, structured tools such as this have the potential to facilitate improved outcomes.
HöglundM. Epidemiology of chronic myeloid leukaemia. In: Hematological malignancies [internet]. Cham: Springer International Publishing, 2021, pp.37–48.
2.
Surveillance, Epidemiology, and End Results Program (US). National Cancer Institute. Cancer stat facts: chronic myeloid leukemia (CML) [Internet]. 2023.
3.
MughalTIRadichJPDeiningerMW, et al.Chronic myeloid leukemia: reminiscences and dreams. Haematologica2016; 101: 541–558.
4.
HehlmannR. Chronic myeloid leukemia in 2020. HemaSphere2020; 4: e468.
5.
RéaDHughesTP. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1. Crit Rev Oncol Hematol2022; 171: 103580.
6.
ParalikarS. From gloom to glee with imatinib: the story of the drug that conquered chronic myeloid leukemia. Natl J Pharmacol Ther2023; 1: 22–25.
7.
TanBKBeePCChuaSS, et al.Monitoring and improving adherence to tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a systematic review. Patient Prefer Adherence2021; 15: 2563–2575.
8.
National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: chronic myeloid leukemia [Internet]. 2022 [cited 2023 Jul 2]. Available from: https://www.nccn.org/patients.
9.
ÖzdemirZNKiliçaslanNAYilmazM, et al.Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities. Int J Hematol2023; 117: 3–15.
10.
Brasil. Ministério da Saúde. Protocolo clínico e diretrizes terapêuticas: leucemia mieloide crônica no adulto. Portaria Conjunta n° 4, de 1° de março de 2021.
11.
MarinDBazeosAMahonFX, et al.Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol2010; 28: 2381–2388.
12.
BeumerJHPillaiVCPariseRA, et al.Human hepatocyte assessment of imatinib drug - drug interactions: complexities in clinical translation. Br J Clin Pharmacol2015; 80: 1097–1108.
13.
ReffMJShillingburgAShahB, et al.Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: practice considerations. J Oncol Pharm Pract2020; 26: 156–174.
14.
SchifferCA. Diagnosis and treatment of chronic myeloid leukemia. In: Neoplastic diseases of the blood. Cham: Springer, 2018, pp.49–68.
15.
MorottiAFavaCSaglioG. Milestones and monitoring. Curr Hematol Malig Rep2015; 10: 167–172.
16.
MichelCBurchertAHochhausA, et al.Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German chronic myeloid leukemia-study IV. Haematologica2019; 104: 955–962.
17.
HochhausASausseleSRostiG, et al.Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol2017; 28: iv41–iv51.
18.
RichardCGlaserELussierMT. Communication and patient participation influencing patient recall of treatment discussions. Health Expect2017; 20: 760–770.
19.
JørgensenKRendtorffJD. Patient participation in mental health care: perspectives of healthcare professionals. Scand J Caring Sci2018; 32: 490–501.
20.
HerledanCCerfonMABaudouinA, et al.Impact of pharmaceutical care interventions on multidisciplinary care of older patients with cancer: a systematic review. J Geriatr Oncol2023; 14: 101450.
21.
OsterbergLBlaschkeT. Adherence to medication. N Engl J Med2005; 353: 487–497.
22.
HeineySPSorrellMShengJ, et al.Interventions to improve adherence to tyrosinekinase inhibitors inchronicmyeloidleukemia: a systematic review. Am J Clin Oncol2021; 44: 291–298.
23.
McCueDALohrLKPickAM. Improving adherence to oral cancer therapy in clinical practice. Pharmacotherapy2014; 34: 481–494.
24.
Al-DewikNMorsiHSamaraM, et al.Is adherence to imatinib mesylate treatment among patients with chronic myeloid leukemia associated with better clinical outcomes in Qatar?Clin Med Insights Oncol2016; 10: 95–104.
25.
HaqueRShiJChungJ, et al.Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO. J Am Pharm Assoc2017; 57: 303–310.
26.
HyvertSYailianALHaesebaertJ, et al.Association between health literacy and medication adherence in chronic diseases: a systematic review. Int J Clin Pharm2023; 45: 38–51.
27.
YeLZhangX. Visualizing the knowledge structure of medication-adherence research: a bibliometric analysis (1997-2016). Int J Health Plann Manage2019; 34: 1333–1353.
28.
BlaschkeTFOsterbergLVrijensB, et al.Adherence to medications: insights from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol2012; 52: 275–301.
29.
NeiheiselMBWheelerKJRobertsME. Medication adherence part one: understanding and assessing the problem. J Am Assoc Nurse Pract2014; 26: 49–55.
30.
KripalaniSRisserJGattiME, et al.Development and evaluation of the adherence to refills and medications scale (ARMS) among low-literacy patients with chronic disease. Value Health2009; 12: 118–123.
31.
JabbourEJKantarjianHEliassonL, et al.Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol2012; 87: 687–691.
32.
ZhaoQWuZELiB, et al.Recent advances in metabolism and toxicity of tyrosine kinase inhibitors. Pharmacol Ther2022; 237: 108256.
33.
FilppulaAMNeuvonenPJBackmanJT. In vitro assessment of the role of CYP3A4 and CYP2C8 in the metabolism of imatinib and interactions with antifungal azoles. Basic Clin Pharmacol Toxicol2014; 114: 362–370.
34.
van LeeuwenRWFvan GelderTMathijssenRHJ, et al.Drug - drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol2014; 15: e315–e326.
35.
Novartis. Drug - drug interactions with imatinib: clinical and pharmacokinetic considerations. Blood2005; 105: 663–670.
36.
WangYZhouQZhuW, et al.Pharmacokinetic interactions between tyrosine kinase inhibitors and antiepileptics: focus on CYP3A4 induction. Front Pharmacol2020; 11: 574170.
37.
SatoYMasudaSOtsuboK, et al.Alectinib - warfarin interaction necessitating warfarin dose increase in a patient with ALK-positive non-small cell lung cancer. Clin Case Rep2023; 11: e7140.
38.
van LeeuwenRWFJansmanFGAvan den BemtPMLA, et al.Drug - drug interactions between oral anticancer drugs and concomitant medications. Eur J Cancer2013; 49: 3821–3832.
39.
RostiGCastagnettiFGugliottaG, et al.Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Nat Rev Clin Oncol2017; 14: 141–154.
